Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQian Chu

About this trial

This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.

Eligibility criteria

Qualifiers

Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC

Age ≥ 18 years

Receiving definitive chemoradiotherapy

Able and willing to complete electronic questionnaires

Disqualifiers

Severe comorbidities (heart, liver, kidney)

Psychiatric illness or cognitive impairment

Prior chest or mediastinal radiotherapy

Trial design

Treatments tested in this trial

  • Electronic Patient-Reported Outcome Monitoring

Treatment groups

No treatment groups listed

Sponsors and collaborators

Qian Chu

Lead sponsor

Tongji Hospital

Sponsor institution